Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.
This announcement was covered in Yahoo Finance, The Canadian Business Journal, Global News Wire, and BioSpace.
Applied immediately after surgical wound closure, SCX-001 reduces the amount of scar tissue that develops during the body’s natural healing process. The 24-subject Phase I clinical trial will be conducted at ...
MaRS Innovation was highlighted in the Networks of Centres of Excellence (NCE) newsletter on Wednesday, June 22. The article is titled, "MaRS Innovation revolutionizes approach to commercialization, " and discusses the success of the MaRS Innovation commercialization model.
The article mentions companies such as ScarX Therapeutics, a spin-off of MI and Toronto’s Hospital for Sick Children that is commercializing a topical prescription cream. It also talks about Encycle Therapeutics, a Toronto biotechnology start-up from the University of Toronto, that has developed a fast, ...
Joel Liederman, MaRS Innovation's vice-president of Business Development and Commercialization for physical sciences, is attending BioTransfer 2014 on March 18 to chair the Medical Devices Committee.
This is the first year that Toronto is hosting the BioTransfer conference. Presenters at the one-day event will discuss biotherapeutics, diagnosis and medical technology. The conference's goal is to share knowledge on current trends in the industry and to stimulate collaboration with private sector companies.
As chair, Liederman will open the medical devices committee panel discussion on Tuesday afternoon ...
MaRS Innovation's President and CEO, Dr. Raphael (Rafi) Hofstein, was appointed to the Quebec Consortium for Drug Discovery (CQDM) Board of Directors on February 18.
CQDM is a Quebec-based not-for profit that funds and supports joint projects in private and biopharmaceutical sectors.
Here's an excerpt from CQDM's announcement:
Dr. Hofstein, actively involved in the field of biotechnology, partnerships and technology transfer for over 30 years, greatly contributed to defining Israel as a world leader in biotechnology. In Israel, Dr. Hofstein held various positions including R & D Manager ...
In "Big-Brain Hunting: The Key to Supercluster Success," the Huffington Post's Pat Lynch investigates how and what makes start-ups successful. Attracting top-talent is listed as a major reason, but so is the environment required to give start-ups the tools they need to flourish.
Lynch highlights MaRS Innovation as a driving force in sustaining the innovation industry in Canada by attracting big ideas and global talent, using former MI project manager Lyssa Neel as an example.
Neel helped launch the education sector start-up Crowdmark, and ...
Council members include MI’s Raphael Hofstein and MI Board Chair Dr. Robert Bell
On November 20, the Government of Ontario launched the Ontario Health Innovation Council to support health innovation in Ontario. Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was named to the council.
By becoming a member of the Council, Hofstein will assist in identifying evidence-based opportunities in Ontario’s healthcare space and advancing them into practice on a global scale. (more…)